Taysha Gene Therapies, Inc. Shareholders' Equity
Taysha Gene Therapies, Inc. (TSHA) had Shareholders' Equity of $387.27 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $387.27M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $211.94M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $246.94M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $218.99M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $387.27M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $211.94M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $246.94M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $218.99M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $248.73M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $55.06M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $71.53M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $88.80M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $108.87M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $53.85M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $74.94M 10-K · filed 2026-03-19 | |
| 2023-09-30 | -$49.11M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$37.11M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | -$14.95M 10-Q · filed 2024-08-12 | |
| 2022-12-31 | $949.00K 10-K · filed 2025-02-26 | |
| 2022-09-30 | $10.70M 10-Q · filed 2023-11-14 | $11.13M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $32.51M 10-Q · filed 2023-11-14 | $32.71M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $50.74M 10-Q · filed 2023-08-14 | $50.73M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $95.38M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $140.39M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $186.50M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $222.87M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $251.30M 10-K · filed 2023-03-28 | |
| 2020-09-30 | $267.64M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$26.79M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$5.57M 10-Q · filed 2021-08-16 | |
| 2019-12-31 | -$135.00K 10-K · filed 2022-03-31 | |
| 2019-09-30 | -$31.00K 10-Q · filed 2020-11-12 | |
| 2019-09-20 | $0.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |